Each group consisted of similar mean tumor volumes at the start of treatment with 90 mm3, 94 mm3, 98 mm3 and 88 mm3 for PBS control, anti-VEGF, anti-Ang-2 and CrossMab, respectively. This evidence concerns the gene VEGFA and neoplasm.